Unicancer R&D publications

2018

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large ...

Elvire Pons-Tostivint et al, Annals of Surgical Oncology ; February 2019, Volume 26, Issue 2, pp 356–365

2018

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with ...

Luc Cabel et al, Breast Cancer Research and TreatmentJanuary 2019, Volume 173, Issue 2, pp 397–406.

2018

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Elisa Gobbini et al, European Journal of Cancer 96 (2018) 17e24.

2018

Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 ...

Lieske H. et al, JNCI Cancer Spectrum, Volume 2, Issue 2, 1 April 2018.

2018

GEMO, a national resource to study genetic modifiers of breast and ovarian cancer risk in BRCA1 and BRCA2 pathogenic ...

Lesueur F. et al, Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018.

2018

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk in Women with BRCA1 and BRCA2 mutations

Terry MB et al, JNCI Cancer Spectr. 2018 Dec;2(4):pky078. doi: 10.1093/jncics/pky078. Epub 2019 Mar 8.

2018

Efficacy of Anthracycline/taxane based neoadjuvant chemotherapy on Triple-Negative Breast Cancer in BRCA1 / BRCA2 ...

Bignon L. et al, Breast J 2018 Volume24, Issue3May/June 2018Pages 269-277. Article DOI: 10.1111/tbj.12887

2018

Recommandations françaises du Groupe Génétique et Cancer pour l’analyse en panel de gènes dans les prédispositions ...

Jessica Moretta et al, Bull Can 2018 oct;10 (105) doi : 10.1016/j.bulcan.2018.08.003

2018

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with ...

X. Liang et al, J Hematol Oncol. 2018 Oct 11;11(1):124. doi: 10.1186/s13045-018-0670-9.